Involvement of nitric oxide in phencyclidine-induced hyperlocomotion in mice.
Y Noda, K Yamada, H Furukawa, Toshitaka Nabeshima
European Journal of Pharmacology November 24, 1995 DOI: 10.1016/0014-2999(95)00464-x (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental animal study Peer reviewed |
|---|---|
| Population | Mice |
| Interventions | L-NAME 7-nitro indazole D-NAME L-arginine D-arginine L-lysine |
| Dose | PCP 1, 3, and 10 mg/kg s.c.; L-NAME 5 and 50 mg/kg i.p.; 7-nitro indazole 25 mg/kg; D-NAME 50 mg/kg; L-arginine 1 g/kg i.p.; D-arginine 1 g/kg i.p.; L-lysine 1 g/kg i.p. |
| Key findings | L-NAME (5 and 50 mg/kg) and 7-nitro indazole (25 mg/kg) significantly enhanced PCP (3 mg/kg)-induced hyperlocomotion, an effect prevented by L-arginine but not by D-arginine or L-lysine; D-NAME had no effect. L-NAME slightly enhanced PCP-induced ataxia but did not alter other stereotyped behaviors or motor coordination deficits. The authors suggest central nitric oxide production is involved in mediating PCP-induced behaviors, particularly hyperlocomotion. |
Abstract
The present study was undertaken to investigate the involvement of nitric oxide (NO) in the behaviors induced by 1-(1-phenylcyclohexyl) piperidine (phencyclidine; PCP) in mice, using N(G)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of NO synthase. PCP (1, 3, and 10 mg/kg s.c.) dose dependently induced hyperlocomotion and stereotyped behaviors, including sniffing, head movement, and ataxia, in mice. PCP also caused a marked deficit of motor coordination in mice, the effect being exerted in a dose-dependent manner. Although pretreatment with L-NAME (50 mg/kg i.p.) slightly enhanced the ataxia induced by PCP (3 mg/kg), it failed to modify other stereotyped behaviors and the lack of motor coordination induced by PCP (2 mg/kg). The hyperlocomotion induced by PCP (3 mg/kg) was significantly enhanced by L-NAME (5 and 50 mg/kg) and 7-nitro indazole (25 mg/kg), but not by D-NAME (50 mg/kg), a less active enantiomer of L-NAME. However, the behavioral changes induced by PCP, at the high dose, 10 mg/kg, were not enhanced by L-NAME and D-NAME. The enhancing effects of L-NAME on the PCP (3 mg/kg)-induced hyperlocomotion were significantly prevented by L-arginine (1 g/kg i.p.). However, D-arginine (1 g/kg i.p.) and L-lysine (1 g/kg i.p.) had no effect in this regard. These results suggested the involvement of central NO production in the mediation of PCP-induced behaviors, hyperlocomotion in particular, in mice.
Citations in the library
Cited by 3
- Blockade of phencyclidine-induced effects by a nitric oxide donor. British Journal of Pharmacology July 1, 2000
- The neuronal selective nitric oxide inhibitor AR-R 17477, blocks some effects of phencyclidine, while having no observable behavioural effects when given alone. Pharmacology & Toxicology May 1, 1999
- Role of nitric oxide in the development of tolerance and sensitization to behavioural effects of phencyclidine in mice. British Journal of Pharmacology April 1996
Cites 4
- Recent advances in the phencyclidine model of schizophrenia American Journal of Psychiatry October 1, 1991
- The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate British Journal of Pharmacology June 1, 1983
- Phencyclidine-induced head-weaving observed in mice after ritanserin treatment. European Journal of Pharmacology July 9, 1987
- Effects of risperidone on phencyclidine-induced behaviors: comparison with haloperidol and ritanserin. The Japanese Journal of Pharmacology October 1994